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Summary: Two batches of the highly purified thyroid hormone-binding plasma proteins, human thyropexin
and transthyretin, which were prepared in gram quantities for use in animal experiments, were subjected to
analysis by isoelectric focussing. Under these conditions, it was observed that human transthyretin was
composed of two components. This was presumably due to the use of 8 mol/1 urea. The preparations of both
human transthyretin and human thyropexin contained some products of decomposition which probably arose
in the course of the purification processes and, in addition, possibly also contained some normal genetic
variants of human thyropexin. In spite of the alterations, both protein preparations largely retained their
thyroid hormone-binding capacity, which is essential for in vivo studies on the re-entry of thyroid hormones
from the extravascular space into the circulation. For therapeutic use in thyrotoxicosis, human transthyretin
seems to be preferable to human thyropexin.
Introduction
The main thyroid hormone-binding plasma proteins
in humans are thyropexin (1) ("TGB", human thy-
roxine binding inter-alpha globulin (2))1) and trans-
thyretin (human thyroxine binding prealbumin) (3).
Intravenously injected preparations of either human
thyropexin or human transthyretin induced a rapid
re-entry of large amounts of both radioactive and
non-labeled triiodothyronine (T3) and thyroxine (T4)
from the extravascular space into the circulation in
experiments in rabbits (4, 5). The physiological prin-
ciple of passive transport of thyroid hormones, me-
diated by thyropexin and transthyretin, might be ex-
ploitable as a novel approach to the treatment of
') No reasonable word combinations for medical terminology
can be formed with the acronym "TBG", e. g., "a-TBG-
aemia", "hypo-TBG-aemia", "dys-TBG-aemia" or "hyper-
TBG-aemia". It was therefore suggested that the generic
name "thyropexin" be substituted for "TBG" and for "thy-
roxine binding inter-alpha globulin".
severe thyrotoxicosis in emergencies: The concentra-
tion of both T4 and T3 in the plasma can be signifi-
cantly enhanced by i.v. injection of either human
thyropexin or human transthyretin, thereby making
T4 and T3 accessible to elimination by means of
plasma exchange or plasmapheresis. In our previous
experiments, however, the T4-binding ability of the
human thyropexin preparation appeared to be slightly
reduced (4). The integrity of the human thyropexin
and human transthyretin preparations employed was
therefore investigated by means of isoelectric focuss-
ing experiments.
Materials and Methods
Proteins
Since neither human thyropexin nor human transthyretin were
commercially available in large quantities, specially purified
human thyropexin and human transthyretin preparations were
made by the Behringwerke (Marburg/L., Germany) specifically
for the animal experiments described in a previous paper (4).
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Isoelectric focussing
For the isoelectric focussing (6, 7) experiments, polyacrylamide
gels (Pharmacia-LKB, Freiburg, Germany) containing 8 mol/1
urea were employed. Carrier ampholytes (Pharmacia-LKB,
Freiburg) were:
for human thyropexin:
0.2 ml pH 3.5-10.0; 0.2 ml pH 3.5-5.0;
0.2 ml pH 5-7; 0.4 ml pH 4.6;
for human transthyretin:
0.2 ml pH 3.5-10.0; 0.2 ml pH 5-7; 0.6 ml pH 4-6.
Focussing procedure: Macrodrive®-5 power supply, Multi-
phore® electro-focussing unit (LKB, Freiburg, Germany).
Running conditions: 8 °C, 1500V, 15mA; prefocussing in 2-
Watt steps, 10 min each until 10 Watts were reached; total IEF
time 3-4.5h. Anolyte, 1 mol/1 H3PO4; catholyte, 1 mol/1
NaOH.
Either 8 μΐ undiluted human donor plasma (controls) or 8 μΐ
purified human thyropexin or human transthyretin (both from
Behringwerke, Marburg/L., Germany, or from UCB Bioprod-
ucts, Braine-L'AUeud, Belgium) were placed on the gel with
5 x 5 mm filter papers (Pharmacia-LKB, Freiburg, Germany),
human thyropexin 1.5 cm from the cathode, human transthyr-
etin 1.2 cm from the anode.
Western-blotting and EIA
The proteins were passively transferred from the gel to nitro-
cellulose membranes (NCM 0.45 μπι, Schleicher & Sch ll, Ein-
beck, Germany) by contact diffusion for 1 h; washing steps
were performed in phosphate-buffered saline solution contain-
ing 500 mg/1 Tween 20® (Merck, Darmstadt, Germany); mem-
branes were blocked with 50 g/1 bovine serum albumin
(SIGMA, Deisenhofen b. M nchen, Germany) in phosphate-
buffered saline solution pH 7.4. First antibodies were goat anti-
human thyropexin (Merz & Dade) 1 :200 in a phosphate-
buffered saline solution containing 10 g/1 bovine serum albumin.
Rabbit anti-goat immunoglobulin with conjugated peroxidase
(Merz & Dade) served as second antibody. This was diluted
1 : 200 with a solution containing 10 g/1 bovine serum albumin.
First and second antibodies were reacted l h each successively;
visualization was by o-toluidine-dependent peroxidase reac-
tions.
Results
As shown in figure la, the thyropexin preparation
from UCB Bioproducts (middle plate, track No. 1)
reacted only faintly with the homologous antibody,
although this human thyropexin was applied in a two-
to threefold higher concentration than the other prep-
aration (Nos. 2 and 3). The human thyropexin prep-
aration in tracks 2 and 3 exhibited heavy trailing,
probably due to partial polymerization in the course
of purification. Neither the human thyropexin from
UCB Bioproducts nor the human thyropexin from
the Behringwerke was contaminated by the vitamin
D3-binding group-specific components Gc 2-1 F or
Gc 1 F (tracks 3 and 4 of left-hand plate). Moreover,
no antigen-antibody reaction was observed with the
αι-proteinase inhibitor in tracks 3 and 4 of the right-
hand plate.
As shown in figure Ib, the two main bands of the
purified transthyretin preparation from Behringwerke
(2nd plate from left, track No. 1) were corresponded
to the two-banded pattern of native human transthy-
retin (track Nos. 2—4). The purified human transthy-
retin, however, contained numerous additional frac-
tions not representing cross-reacting group-specific
components Gc, retinol binding protein, or arpro-
teinase inhibitor (track No. 2 in plates 1, 3 and 4 from
left). The retinol binding protein has apparently been
lost in the course of the purification process.
Discussion
In previous experiments (4), the thyroxine-binding
capacity of the highly purified thyropexin preparation
from Behringwerke was compared with the thyroxine
binding capacity of the purified human thyropexin in
the serum of an analbuminaemic subject. The thyrox-
ine binding capacity of the purified human thyropexin
was only 2A to 3Λ of the thyroxine binding capacity
of native human thyropexin. As demonstrated in the
present paper, this decrease of thyroxine binding ca-
pacity was probably due to unavoidable alterations
of human thyropexin in the course of the purification
process, giving rise to numerous degradation pro-
ducts. Similar effects apparently occurred with human
transthyretin. These degradation products of human
thyropexin or human transthyretin still reacted with
either anti-human thyropexin or anti-human trans-
thyretin antibodies exclusively. This was concluded
from the fact that the anti-human thyropexin and
anti-human transthyretin antibodies used showed no
cross-reactions with serum proteins other than human
thyropexin or human transthyretin, respectively.
Thus, the degradation products of the purified human
thyropexin and human transthyretin preparations dis-
played altered physico-chemical properties, but they
were antigenically intact. Some of the supposed deg-
radation products of human thyropexin may therefore
also represent individual variants of normal human
thyropexin (8, 9), especially since the human thyro-
pexin was extracted from a pool of hundreds of donor
blood plasma specimens.
In spite of the partial decomposition of the thyroid
hormone-binding proteins, it could be shown in ani-
mal experiments that the re-entry of thyroid hormones
from the extravascular space into the circulation is a
purely passive process (5). As a consequence of this
observation, very large doses of human thyropexin or
human transthyretin might be used as a detoxicant
for the treatment of severe thyrotoxicosis or thyroid
storm, at least theoretically. The doses of human
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 7
Luckenbach et al.: Isoelectric focussing of thyropexin and transthyretin 389
Group-
 α Proteinase
specific Thyropexin inhibitor
components
Group- Retinolur - ι-ieiinoi
 a -Proteinase
specific Transthyretin binding Jhjbitor
components
G C 1 F -
Gc2 -»
- M 1
θ . ..:'**m ^ —Start
a ) 1 2 3 4 5 J 1 2 3 4 5 \ 1 2 3 4 5
protein
— Start
· - · · . . · . . · . - . · , .·;· ·;· - · ·· ·
1 2 3 4| 1 2 3 41 1 2 3 41 1 2 3 4
Fig. 1. Combined isoelectric focussing and immunological detection
(a) Human thyropexin
Identification of tracks, from left to right:
Group-specific components (Gc):
(!)Gc2-lF;
(2)GclF;
(3) human thyropexin from Bioproducts;
(4) human thyropexin from Behringwerke;
(5)GclF.
1st antibody: goat anti-Gc.
Thyropexin:
(1) human thyropexin from Bioproducts, 150 mg/1;
(2) human thyropexin from Behringwerke, 75 mg/1;
(3) human thyropexin from Behringwerke, 50 mg/1;
(4 & 5) native human thyropexin in human serum.
1st antibody: goat anti-thyropexin.
αϊ-Proteinase inhibitor:
(1 & 2) arproteinase inhibitor Μ 1;(3) human thyropexin from Bioproducts;
(4) human thyropexin from Behringwerke;
(5) arproteinase inhibitor Μ 1.
1st antibody: goat anti-arproteinase inhibitor Μ 1.
of purified thyropexin and transthyretin.
(b) Human transthyretin
Identification of tracks, from left to right:
Group-specific components (Gc):
(!)Gc2-lF;
(2) human transthyretin from Behringwerke;
(3&4)GclF.
1st antibody: goat anti-Gc.
Transthyretin:
(1) human transthyretin from Behringwerke;
(2, 3, 4) native human transthyretin in human
serum.
1st antibody: goat anti-human transthyretin.
Retinol binding projtein:
(1) native retinol binding protein in human serum;
(2) human transthyretin from Behringwerke;
(3 & 4) native retinol binding protein in human
serum.
1st antibody: goat anti-retinol binding protein.
αϊ-Proteinase inhibitor:
(1) αι-proteinase inhibitor Μ 1;
(2) human transthyretin from Behringwerke;
(3 & 4) arproteinase inhibitor Μ 1.
1st antibody: goat anti-arproteinase inhibitor Μ 1.
All antibodies were from Merz & Dade.
thyropexin or human transthyretin necessary for just
one single application, however, would correspond to
the human thyropexin or human transthyretin content
of approximately fifty to one hundred litres of human
plasma.
Human serum albumin possesses a much higher T4
binding capacity than human thyropexin or human
transthyretin, but a many times lower T4-binding af-
finity which, in the presence of human thyropexin and
human transthyretin in vitro, amounts to only
5 — 10% of the total thyroxine binding capacity of
whole serum or plasma. Consistent with this, human
serum albumin was ineffective in our animal experi-
ments (4).
At present, human thyropexin cannot be prepared for
clinical use in humans, because it cannot be heat-
sterilized. At temperatures of > 56 °C, human thy-
ropexin loses its thyroxine binding capacity. In addi-
tion, the human thyropexin fraction usually contains
pyrogenic substances that cannot be removed by cur-
rently available purification processes. These consid-
erations do not apply to human transthyretin, which
therefore may be more suitable than human thyro-
pexin as a new detoxicant for the emergency treatment
of thyrotoxicosis.
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